Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|4|368-376

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.4, 2015-04, pp. : 368-376

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma

By  

Current Signal Transduction Therapy, Vol. 8, Iss. 3, 2013-01 ,pp. : 210-218

Bentham Science Publishers

Access to resources Recommend Favorite

Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 44-54

Bentham Science Publishers

Access to resources Recommend Favorite

Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex

By  

EPILEPSIA, Vol. 56, Iss. 7, 2015-07 ,pp. : 1088-1097

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tuberous Sclerosis Complex: Genetic Aspects

By  

THE JOURNAL OF DERMATOLOGY, Vol. 19, Iss. 11, 1992-11 ,pp. : 914-919

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 7, 2015-07 ,pp. : 654-663

John Wiley & Sons Inc

Access to resources Recommend Favorite